GIA632

Phase 2Small molecule

Novartis

GIA632 is one of 64 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

VitiligoActive, not recruiting

Non-Segmental VitiligoRecruiting

Atopic DermatitisPhase 2

Active, not recruiting

VitiligoPhase 2

Active, not recruiting

Non-Segmental VitiligoPhase 2

Recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Skyrizi

AbbVie

Phase 3

2 2

Cytosar

Teva

Phase 3

1 3

Amlitelimab

Sanofi

Phase 3

6 4

Xyzal

CChattem

Phase 3

2 5

Celestone

SSchering-Plough

Phase 3

2 6

Flovent

PParatek Pharmaceuticals Inc

Phase 3

1 7

Calcineurin Inhibitors

Sanofi

Phase 3

1 8

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

4 9

Pegcrisantaspase

Jazz Pharmaceuticals

Phase 3

1 10

SHR-1819

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Atopic Dermatitis

NCT07220577

Q1 2030

Phase 2Recruiting

Non-Segmental Vitiligo

NCT07431177

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Recruiting· Novartis logo

Novartis·Phase 2·NCT07220577·84 enrolled

Non-segmental Vitiligo1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period

Recruiting· Novartis logo

Novartis·Phase 2·NCT07431177·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GIA632. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GIA632 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GIA632. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

GIA632

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2030

Trials by Indication[1]

Atopic Dermatitis1 trial

Non-segmental Vitiligo1 trial

References

Drug Info

Quick Facts

Related News